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Mitochondrial dysfunction in muscle has been implicated to play a causative role or being an indirect consequence of insulin resistance in 
type-2 diabetes. In order to investigate potential diabetes-related alterations in the mitochondrial proteome of muscle, we have carried out a 
mass spectrometry-based proteomic analysis of the gastrocnemius muscle from normal versus diabetic Goto-Kakizaki rats. A generally per-
turbed protein expression pattern was observed in the mitochondria-enriched fraction from diabetic muscle. Various mitochondrial markers, 
including NADH dehydrogenase, cytochrome b-c1 complex and isocitrate dehydrogenase were reduced in diabetic preparations. Isoforms of 
pyruvate dehydrogenase and ATP synthase exhibited differential changes in their abundance. The altered protein expression levels of these key 
metabolic enzymes might trigger a diabetes-dependent decrease in mitochondrial oxidative phosphorylation levels. The proteomic findings 
presented here support the idea that mitochondrial abnormalities are involved in the molecular pathogenesis of type-2 diabetes and may be 
crucial for the development of insulin resistance. 
Keywords: Diabetes; DIGE; Goto-Kakizaki Rat; Mitochondria; Muscle Proteomics. 
1. Introduction 
Besides being involved in intermediary metabolism, protein 
transport, cell cycle progression, calcium signaling and regu-
lation of apoptosis, mitochondria represent the primary site 
for energy generation via oxidative phosphorylation [1]. Al-
tered functioning or changed expression levels of mitochon-
drial proteins play a key role during development, natural 
aging and in various pathologies [2, 3]. Mass spectrometry-
based subproteomics suggests itself as an ideal analytical 
method to determine global changes in the mitochondrial 
protein complement [4-6]. Proteomic screening of mito-
chondrial preparations suggest the existence of approximate-
ly 1,500 individual mitochondrial protein species, whereby 
considerable tissue-specific differences exist within the mito-
chondrial proteome [4]. The recent difference in-gel electro-
phoretic analysis of the mitochondria-enriched fraction from 
aged rat skeletal muscle has revealed drastic changes in many 
metabolic enzymes involved in oxidative phosphorylation [7]. 
The natural functional decline of the aged neuromuscular 
system is clearly associated with a shift to more oxidative-
aerobic metabolism in a slower twitching fibre population 
[8]. In analogy, we have used here a similar proteomic ap-
proach to determine whether type-2 diabetes is associated 
with significant alterations in the mitochondrial proteome 
from skeletal muscle. We have focused our two-dimensional 
gel electrophoretic study on the pH 4 to 7 range since most 
soluble mitochondrial proteins can be separated in this acidic 
to neutral environment. 
Impaired glucose homeostasis and diabetic complications 
affect millions of patients worldwide [9]. Insulin resistance 
impinges especially on contractile fibres, making abnormal 
glucose handling in skeletal muscle tissues a key issue for 
treating side effects of type-2 diabetes [10]. The etiology of 
diabetes mellitus appears to be influenced by both environ-
mental and genetic factors, whereby obesity and a sedentary 
lifestyle have an extremely negative influence on disease pro-
gression [11]. Many diabetics suffer from glucotoxic side 
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effects and severely disturbed metabolic homeostasis [12]. 
Since muscle fibres are the most abundant cell type in the 
body and skeletal muscles represent the major organ for insu-
lin-mediated whole body glucose disposal, insulin resistance 
in the musculature is one of the most striking pathophysio-
logical features of type-2 diabetes [13]. In this respect, cellular 
dysfunction of muscle mitochondria is believed to play a 
crucial part in triggering insulin resistance [14-16]. It is not 
clear whether mitochondrial abnormalities are a secondary 
consequence of impaired hormonal signaling or the actual 
primary cause for a diminished glucose uptake into peripher-
al tissues [17]. However, independent of the exact initial role 
of mitochondria in diabetes, the long-term pathological con-
sequences of disturbed mitochondrial bioenergetic functions 
are clearly a decline in crucial ATP-dependent cellular pro-
cesses [16]. 
In order to determine potential diabetes-related changes in 
the mitochondrial subproteome from skeletal muscle, we 
have performed here a mass spectrometry-based proteomic 
analysis of the gastrocnemius muscle from normal versus 
diabetic Goto-Kakizaki (GK) rats. The non-obese GK animal 
model of type-2 diabetes is a spontaneously diabetic rat that 
shows clear signs of faulty insulin signaling within 4 weeks 
after birth [18]. GK rats exhibit increased levels of blood glu-
cose, but no major changes in the concentration of non-
fasting plasma insulin [19]. Diabetic GK skeletal muscles 
show: (i) an inhibition of insulin receptor auto-
phosphorylation [20], (ii) impaired activities of insulin sig-
naling intermediates [21], (iii) a diminished recruitment of 
the glucose transporter GLUT4 [22], (iv) membrane cytoskel-
etal defects in the dystrophin-dystroglycan complex [23], (v) 
a reduced percentage of oxidative fibres [24], (vi) a generally 
perturbed protein expression pattern [25], and (vii) abnormal 
mitochondrial functioning [26]. 
The proteomic analysis of the mitochondria-enriched frac-
tion from normal versus diabetic skeletal muscles presented 
here has revealed a reduced expression of several mitochon-
drial enzymes, including NADH dehydrogenase, cytochrome 
b-c1 complex and isocitrate dehydrogenase. The changed 
abundance of these metabolic proteins might play a central 
role in the well-established decrease of mitochondrial oxida-
tive phosphorylation in diabetic fibres. Hence, the proteomic 
results shown in this report have demonstrated that the mito-
chondrial subproteome is altered in type-2 diabetes and sug-
gest that the changed density of key mitochondrial enzymes 
might aid in the pathological development of insulin re-
sistance. 
2. Material and methods 
2.1 Materials 
For the gel electrophoretic separation of muscle proteins, 
materials and analytical-grade chemicals were purchased 
from Amersham Biosciences/GE Healthcare, Little Chalfont, 
Buckinghamshire, UK (Imobiline IPG dry-strips, ampholytes, 
acetonitrile, Destreak agent, iodoacetamide, CyDye DIGE 
fluor minimal dyes Cy3 and Cy5), Biorad Laboratories, Hem-
el-Hempstead, Hertfordshire, UK (Laemmli-type buffer sys-
tem; protein molecular mass markers) and National Diagnos-
tics, Atlanta, GA, USA (ultrapure Protogel acrylamide stock 
solution). Protease inhibitors were obtained from Roche Di-
agnostics (Mannheim, Germany). Sequencing grade-
modified trypsin was from Promega, Madison, WI, USA. 
Nitrocellulose transfer stacks were from Invitrogen (Carls-
bad, CA, USA) and chemiluminescence substrate was pur-
chased from Roche Diagnostics (Manheim, Germany). Pri-
mary antibodies ab66484 to mitofilin  and ab14730 to the 
beta-subunit of mitochondrial ATP synthase were obtained 
from Abcam Ltd. (Cambridge, UK). Peroxidase-conjugated 
secondary antibodies were obtained from Chemicon Interna-
tional (Temecula, CA, USA).All other chemicals used were of 
analytical grade and purchased from Sigma Chemical Com-
pany, Dorset, UK. 
2.2 Preparation of mitochondria-enriched fraction from skele-
tal muscle 
Gastrocnemius muscle tissue (3g wet weight) from 9-week 
old normal versus age-matched diabetic GK rats was cut into 
small pieces and homogenised in 20 ml of buffer (220mM 
mannitol, 70mM sucrose, 20mM Hepes, pH 7.4), supple-
mented with 1 Roche PIC complete mini tablet per 10 ml of 
solution [7]. The resulting mixture was centrifuged at 1,100g 
for 5 min at 4oC to remove cellular debris. The supernatant 
was retained. The pellet was re-suspended in 10 ml of ho-
mogenisation buffer and re-centrifuged as described above. 
Supernatants from the above separation steps were pooled 
and centrifuged at 7,000g for 15 min. The mitochondrial 
fraction was obtained as a pellet after repeated centrifugation 
steps at 20,000g for 15 min. The final mitochondria-enriched 
pellet was re-suspended in 2D lysis buffer for DIGE analysis. 
Samples were adjusted to a pH-value of 8.5. The protein con-
tent of individual samples was determined by the Bradford 
assay system [27]. 
2.3 Fluorescent labelling of proteins  
Potential differences in the protein expression patterns of 
normal versus diabetic mitochondria were determined by 
difference in-gel electrophoresis (DIGE) using the CyDye 
DIGE fluor minimal dyes Cy3 and Cy5. DIGE dyes were re-
constituted as a stock solution of 1mM in fresh dimethylfor-
mamide [9]. The stock solution was diluted to a working 
solution of 0.2mM prior to fluorescent labelling. Samples of 
50 mg protein, representing each biological replicate, were 
minimally labelled with 200 pmols of Cy3 working solution. 
A pooled sample consisting of equal quantities of protein 
from all replicates used in the experiment were labelled at 200 
pmol of Cy5 working solution to 50 mg of protein. The 
pooled fraction served as an internal standard. All samples 
were labelled at pH 8.5 with the appropriate amount of 
CyDye and after brief vortexing incubated on ice in the dark 
for 30 min. For the electrophoresis of individual gels, Cy3- 
and Cy5-labelled samples were mixed at an equal ratio. The 
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labeling reaction was terminated by the addition of 1µl of 10 
mM lysine per 25 µg of muscle protein. Suspensions were 
briefly vortexed and then centrifuged at 12,000g for 10s and 
incubated on ice in the dark for 10 min. For gel electropho-
retic separation, samples where loaded onto IPG strips with 
an equal volume of 2x sample buffer (7M urea, 2M thiourea, 
65mM CHAPS, 2% ampholytes and 2% DTT) during rehy-
dration [28]. 
2.4 Two-dimensional gel electrophoresis  
The fluorescently labelled subproteomes from the mito-
chondria-enriched fraction of normal (n=4) versus diabetic 
(n=4) skeletal muscle tissues were separated in the first di-
mension by isoelectric focusing and in the second dimension 
by sodium dodecyl sulphate polyacrylamide gel electrophore-
sis, as previously optimized by our laboratory [25]. All bio-
logical replicates were analyzed individually. IPG strips were 
rehydrated in rehydration buffer (7M urea, 2M thiourea, 4% 
(w/v) CHAPS, 1.2% Destreak agent and 2% (v/v) pH 3-10 
ampholytes) and 700 mg of protein sample for 12 hours. The 
first-dimension protein separation was conducted using the 
IPG strips on an Amersham IPGphor IEF system following 
the protocol previously described in detail [28]. First dimen-
sion strips were subjected to reduction and alkylation prior to 
second-dimension separation on 12.5% (w/v) slab gels. Gels 
were electrophoresed in an Amersham Ettan DALT-Twelve 
system [28]. 
2.5 Image Acquisition and data analysis 
Fluorescently-labeled muscle proteins were visualised with 
the help of a Typhoon Trio variable mode imager from 
Amersham Biosciences/GE Healthcare (Little Chalfont, 
Bucks., UK). Two-dimensional gel images were analysed 
using Progensis SameSpots analysis software version 3.2.3 
from Non Linear Dynamics (Newcastle upon Tyne, UK).  All 
analytical DIGE gels were alligned to a reference gel. Follow-
ing detection and filtering of spots, images were separated 
into groups (Normal rat muscle versus Goto-Kakizaki rat 
muscle) and analysed to determine significant changes in 
two-dimensional spot abundance. A hit list was generated of 
protein species that changed in density. An Anova score was 
included for each spot and any muscle proteins with an Ano-
va score above 0.5 were excluded from further consideration. 
Any two-dimensional protein spot with a significant change 
in abundance was subsequently identified by mass spectrom-
etry. Protein spots were excised from DIGE gels that had 
subsequently been stained with colloidal Coomassie Blue. 
2.6 Mass spectrometric identification of muscle proteins 
In order to identify individual muscle-associated protein 
species, peptide mixtures were analysed by mass spectrome-
try on a Model 6430 Ion Trap LC/MS apparatus from Agilent 
Technologies (Santa Clara, CA, USA). Excision, washing, 
destaining and treatment with trypsin were performed by a 
previously optimised method [7]. Following tryptic digestion, 
generated peptides were obtained by removing supernatants 
from digested gel plugs. Further recovery was achieved by 
adding 30% acetonitrile/0.2% trifluoricacid to the gel plugs 
for 10 min at 37 0C with gentle agitation. Peptide-containing 
supernatants were pooled and samples dried through vacuum 
centrifugation. Peptide mixtures were then re-suspended in 
10µl mass spectrometry-grade water and 0.1% formic acid for 
identification by ion trap LC-MS analysis. Separation of pep-
tides was performed with a nano flow Agilent 1200 series 
system, equipped with a Zorbax 300SB C18 5µm, 4 mm 40nl 
pre-column and a Zorbax 300SB C18 5µm, 43mm x 75µm 
analytical reversed- phase column using the HPLC-Chip 
technology. Mobile phases utilized were A: 0.1% formic acid, 
B: 50% acetonitrile and 0.1% formic acid. Samples (5µl) were 
loaded into the enrichment at a capillary flow rate set to 2 
µl/min with a mix of A and B at a ratio 19:1. Tryptic peptides 
were eluted with a linear gradient of 10-90% solvent B over 2 
µl/min with a constant nano pump flow of 0.6 ml/min. A 1 
min post time of solvent A was used to remove sample carry 
over. The capillary voltage was set to 1700 V. The flow and 
the temperature of the drying gas were 4µl/ min and 300oC, 
respectively [7]. Database searches were carried out with 
Spectrum Mill Work Bench or Mascot MS/MS Ion search 
(Matrix Science, London, UK). 
2.7 Immunoblot analysis 
Standard one-dimensional immunoblotting was carried out 
in order to survey the mitochondrial isolation procedure and 
to validate expression changes in marker proteins as judged 
by DIGE analysis. Our optimized immunoblotting procedure 
for the immuno-decoration of muscle proteins has been pre-
viously described in detail [7]. Crude tissue extracts and the 
mitochondria-enriched fraction from normal versus diabetic 
skeletal muscle were electrophoretically separated with the 
help of a Mini-Protean-3 gel system (BioRad Laboratories, 
Hemel-Hempstead, Herts., UK). Gels were electrophoresed at 
80V until the tracking dye ran off the end of the gel. For im-
munoblotting experiments, gels were transferred to an iblot 
transfer unit from Invitrogen (Carlsbad, CA, USA) for semi-
dry blotting. Electrophoretic transfer was carried out for 6 
min. Nitrocellulose membranes were blocked in a milk pro-
tein solution for 1h and then incubated overnight with gentle 
agitation with sufficiently diluted primary antibody, diluted 
in blocking solution containing 5% (w/v) fat-free milk pow-
der in phosphate-buffered saline (0.9 % (w/v) NaCl, 50 mM 
sodium phosphate, pH 7.4). Following two washing steps 
with blocking solution for 10 min, sheets were incubated for 
1h with secondary peroxidase-conjugated antibodies. Subse-
quently, nitrocellulose sheets were washed twice with block-
ing solution and then rinsed with phosphate-buffered saline. 
Immuno-decorated bands were visualized by the enhanced 
chemiluminescence method. 
3. Results 
Difference in-gel electrophoresis (DIGE) is a highly dis-
criminating technique that can detect minute changes in the 
expression of soluble proteins. This makes DIGE analysis the 
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method of choice for comparative biochemical studies of 
distinct protein complements [29]. Although two-
dimensional gel electrophoresis underestimates the presence 
of certain classes of proteins, such as integral proteins and 
components with a very high molecular mass, the highly sen-
sitive DIGE technique is ideal for the study of soluble pro-
teins in the molecular range of 10 kDa to 200 kDa. We have 
applied here the DIGE method for the comparative analysis 
of the soluble mitochondrial subproteome from normal ver-
sus diabetic skeletal muscle tissue. As illustrated in Figure 1, 
the subcellular fractionation method applied here clearly 
resulted in the enrichment of mitochondrial markers. While 
the fast myosin heavy chain isoform MHCf drastically de-
creased in abundance during the isolation of the mitochon-
drial fraction (Figure 1A), marker proteins of the inner and 
outer mitochondrial membrane, mitofilin and the porin iso-
form VDAC1, increased in their density (Figure 1B, C). Thus, 
this differential centrifugation protocol removed the most 
abundant type of contractile muscle proteins from the mito-
chondrial preparation. 
Following fluorescent labeling with CyDyes and the high-
resolution two-dimensional gel electrophoretic separation of 
the mitochondria-enriched fraction, as shown in Figure 2, 
densitometric scanning revealed a changed abundance in 24 
distinct protein spots. A reduced expression was found for 18 
muscle-associated proteins and an increased density for 6 
proteins in the mitochondria-enriched fraction. The first 
dimensional position of certain muscle-associated proteins, 
such as phosphoglycerate kinase, diacylglycerol kinase and 
phosphofructokinase, did not agree with the theoretical pI-
values of these enzymes. However, the recent large-scale 
analysis of the aged mitochondrial proteome from rat skeletal 
muscle has shown that the mitochondrial organelle contains 
over a thousand different protein species, whereby many 
proteins are represented by a large number of distinct two-
dimensional spots in analytical gels [7]. Thus, a specific type 
of enzyme exists in multiple sub-species and this explains 
why theoretical pI-values do not always perfectly agree with 
actual pI-values following two-dimensional gel electrophore-
sis. It is actually one of the great advantages of proteomic 
technologies that they can differentiate between differently 
charged or sized sub-species of individual proteins. 
The DIGE master gel shown in Figure 3 outlines the posi-
tion of the 24 2D-spots with a changed abundance in diabetic 
preparations. Mass spectrometry identified the proteins with 
a decreased abundance as the glycolytic enzyme enolase 
(spots 1 and 7), the molecular chaperones Hsp60 (spot 3) and 
Hsp72 (spot 8), muscle glycogen phosphorylase (spot 4), the 
mitochondrial enzyme NADH dehydrogenase (spots 5 and 
12), subunit-1 of the cytochrome b-c1 complex (spot 6), 
phosphoglycerate kinase (spot 9) muscle creatine kinase (spot 
10), diacylglycerol kinase (spot 11), isocitrate dehydrogenase 
(spot 13), myosin binding protein H (spot 14), the mitochon-
drial Tu translation elongation factor (spot 16), the 78 kDa 
glucose-regulated protein (spot 17) and the fast MLC1-f  
isoform of  myosin light chain (spot 18). Interestingly, differ-
ential changes of individual 2D spots representing pyruvate 
dehydrogenase (spots 15 and 22) and ATP synthase (spots 2, 
19 and 24) were observed. Increased proteins were identified 
as triose phosphate isomerase (spot 20), phosphofructokinase 
(spot 21) and pyruvate kinase (spot 23). Table 1 correlates 
spot numbers on the DIGE master gel with the proteomic 
information on individual protein species as determined by 
mass spectrometry. The table lists the protein name, acces-
sion number, predicted isoelectric point, predicted molecular 
mass, number of matched peptides, Mascot score, the percent 
sequence coverage and fold-change. The main subcellular 
 
Figure 1. Immunoblot analysis of mitochondrial enrichment 
from normal and diabetic skeletal muscle. Shown are immunob-
lots of crude homogenates versus the mitochondria-enriched frac-
tion from normal (N) versus Goto-Kakizaki (GK) rat muscle, la-
beled with antibodies to the fast MHCf isoform of myosin heavy 
cahin (A), the mitochondrial inner membrane marker mitofilin (B) 
and the mitochondrial outer membrane porin isoform VDAC1 of 
the voltage-dependent anion channel (C). Lanes 1 to 4 show tissue 
homogenates from normal and GK rat muscle and the mitochon-
drial fraction from normal and GK rat muscle, respectively. 
 
Figure 2. Comparative two-dimensional gel electrophoretic 
analysis of normal versus diabetic rat skeletal muscle. Shown is 
the 2D-DIGE analysis of the mitochondria-enriched fraction, using 
a pH 4-7 range in the first dimension. Individual panels represent 
Cy3-labelled gels of mitochondrial protein fractions from normal 
(A) and diabetic GK (C) skeletal muscle, as well as Cy5-labelled 
gels containing pooled standards (B, D). The pH-values of the first 
dimension gel system and molecular mass standards (in kDa) of 
the second dimension are indicated on the top and on the left of 
the panels, respectively. 
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localizations of the identified proteins are predicted to be 
mitochondria (ATP synthase, NADH dehydrogenase, cyto-
chrome b-c1 complex, isocitrate dehydrogenase, pyruvate 
dehydrogenase, F1-ATPase, 78kDa glucose-regulated protein, 
creatine kinase, Tu translation elongation factor, Hsp60), the 
cytosol (enolase, Hsp72, glycogen phosphorylase, phospho-
glycerate kinase, diacylglycerol kinase, triose phosphate iso-
merase, phosphofructokinase, pyruvate kinase) and the con-
tractile apparatus (myosin binding protein H, myosin light 
chain MLC-1f). 
In order to verify DIGE-determined changes in marker 
proteins, immunoblotting was carried out. As shown in Fig-
ure 4, the molecular chaperone Hsp60 was clearly found to be 
reduced in GK preparations (Figure 4A), which agrees with 
the proteomic finding of a reduction in spot no. 3 (Figure 3; 
Table 1). Since the DIGE analysis of mitochondrial ATP syn-
thase had revealed differential effects of diabetes on different 
sub-species of this mitochondrial enzyme, it was of interest to 
evaluate its molecular fate by immunoblotting. As illustrated 
in Figure 4B, the beta-subunit of ATP synthase was found to 
be increased in abundance. This agrees with the proteomic 
identification of increased spot no. 24 (Figure 3; Table 1). The 
statistical evaluation of the comparative immunoblot analysis 
of Hsp60 and mitochondrial ATP synthase is shown in Figure 
4C, D and demonstrates the significance of the altered ex-
pression changes of these two proteins. 
4. Discussion  
Abnormal mitochondrial functioning has been implicated 
to play a central role in the molecular pathogenesis of insulin 
resistance and contractile weakness in diabetic skeletal mus-
cle tissues [17]. The proteomic DIGE analysis of the mito-
chondria-enriched fraction presented here confirms a dis-
turbed protein expression pattern in the mitochondrial sub-
proteome from GK gastrocnemius muscle. Our previous 
proteomic survey of crude total extracts from diabetic GK 
muscle had identified moderate differential expression pat-
terns in 21 protein species. The diabetic phenotype seems to 
be associated with a generally altered composition of the 
muscle protein complement, affecting especially glucose, fatty 
acid, nucleotide and amino acid metabolism, as well as the 
contractile apparatus, the cellular stress response, the anti-
oxidant defense system and detoxification mechanisms [25]. 
With respect to changes in mitochondria, a reduction in 
NADH dehydrogenase, cytochrome b-c1 complex and iso-
citrate dehydrogenase agrees with the previously reported 
decreased oxidative phosphorylation in type-2 diabetes [14-
16]. 
The lower concentration of the molecular chaperones 
Hsp60 and Hsp72 indicates an impaired cellular stress re-
sponse in GK muscle tissue, which might weaken the defense 
mechanisms of metabolically challenged skeletal muscles. 
Reduced levels of muscle glycogen phosphorylase could have 
a negative effect on the proper utilization of stored glycogen 
and a lower concentration of creatine kinase may negatively 
affect the creatine phosphate shuttle. Both reductions in key 
metabolic components probably worsen the bioenergetic 
status of diabetic fibres and explain the contractile weakness 
in certain skeletal muscles from patients with type-2 diabetes 
[30, 31]. Interestingly, glycolytic marker enzymes were differ-
entially affected in GK muscle. The increased density of triose 
phosphate isomerase, phosphofructokinase and pyruvate 
kinase would suggest a higher glycolytic flux rate in tissues 
with a reduced mitochondrial content. Since phosphofructo-
kinase and pyruvate kinase represent rate-limiting steps of 
glycolysis, this alteration might be interpreted as a glycolytic 
 
Figure 3.  Two-dimensional DIGE reference gel of diabetic rat 
skeletal muscle. Shown is a DIGE reference gel of the mitochon-
dria-enriched fraction from rat skeletal muscle, used for the mass 
spectrometric identification of proteins with a differential expres-
sion profile. The pH-values of the first dimension gel system and 
molecular mass standards (in kDa) of the second dimension are 
indicated on the top and on the left of the panel, respectively. Iden-
tified muscle proteins are marked by circles and are numbered 1 to 
24. See Table 1 for a detailed listing of proteins that exhibited a 
diabetes-associated change in their abundance. 
 
Figure 4. Immunoblot analysis of altered marker proteins in 
diabetic skeletal muscle. Shown are immunoblots of normal (lane 
1) versus diabetic Goto-Kakizaki (lane 2) mitochondria-enriched 
preparations from skeletal muscle. Immuno-decoration was carried 
out with antibodies to the molecular chaperone Hsp60 (A, C) and 
the mitochondrial enzyme ATP synthase (B, D). The comparative 
blotting was statistically evaluated using an unpaired Student’s t-test 
(n=5; **p<0.01). 
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shift that has previously been described in obese skeletal 
muscles [32]. On the other hand, the enzymes enolase and 
phosphoglycerate kinase are reduced in GK tissue, which 
might be associated with the multi-functionality of many 
glycolytic elements [33]. The enzyme diacylglycerol kinase 
catalyzes the conversion of diacylglycerol to phosphatidic 
acid and uses ATP as a source of the phosphate. Thus re-
duced ATP levels in diabetic muscle tissues due to a reduced 
content of functional mitochondria could affect this enzyme. 
Altered levels of the fast MLC1-f isoform of myosin light 
chain and myosin binding protein H indicate a certain degree 
of re-modeling of the contractile apparatus. However, since 
this subproteomic analysis was carried out with a mitochon-
dria-enriched fraction, it is difficult to interpret changes in 
regulatory elements of the acto-myosin filaments. Compensa-
tory mechanisms to counter-act the loss of mitochondrial 
functioning appear to be an increase in certain isoforms of 
pyruvate dehydrogenase and ATP synthase [17].  
 In conclusion, the novel candidate proteins with a changed 
expression level in the mitochondria-enriched fraction, as 
shown in this proteomic survey of the GK rat model of non-
obeses type-2 diabetes, should be helpful for complementing 
the biomarker signature of diabetes mellitus [34-38]. Changes 
in the functioning and/or density of mitochondrial enzymes 
Table 1.  List of identified proteins that exhibit a changed abundance in mitochondria-enriched fraction from diabetic skeletal muscle. 
Spot 
no. Protein name Accession no. 
Isoelectric  
point (pI) 
Molecular  
mass (kDa) 
Matched 
peptides 
ANOVA 
(p value) 
Mascot 
score 
Coverage 
(%) 
Fold 
change 
1 Enolase gi|126723393| 7.08 47,332 17 0.009 314 44 -4.5 
2 Mitochondrial H-ATP synthase gi|220904| 5.78 18,828 3 0.021 74 16 -3.3 
3 Heat shock protein Hsp60 gi|56383| 5.11 61,101 5 0.043 100 12 -3.2 
4 Muscle glycogen phosphorylase gi|158138498| 6.65 97,749 10 0.032 112 13 -3.1 
5 NADH dehydrogenase, FeS protein 8 gi|157821497| 5.87 24,419 6 0.031 56 25 -2.9 
6 Cytochrome b-c1 complex, subunit 1  gi|51948476|  5.57 53,511 9 0.004 241 19 -2.7 
7 Enolase gi|126723393| 7.08 47,332 17 0.002 206 44 -2.6 
8 Heat shock protein Hsp72 gi|347019| 5.43 71,116 12 0.011 113 17 -2.6 
9 Phosphoglycerate kinase  gi|40254752| 8.02 44,916 9 0.003 96 29 -2.5 
10 Muscle creatine kinase gi|6978661| 6.57 43,224 7 0.015 111 17 -2.4 
11 Diacylglycerol kinase, delta gi|149037714| 8.09 126,993 2 0.008 50 1 -2.3 
12 NADH dehydrogenase, FeS protein 1 gi|53850628| 5.65 80,348 2 0.032 44 4 -2.2 
13 Isocitrate dehydrogenase gi|16758446| 6.47 40,052 7 0.049 198 22 -2.2 
14 Myosin binding protein H gi|38303941| 6 53,044 7 0.048 177 23 -2.1 
15 Pyruvate dehydrogenase gi|56090293| 6.2 39,305 11 0.031 294 34 -2.1 
16 Tu translation elongation factor, mitochondrial gi|149067905| 7.65 44,023 2 0.020 74 10 -2 
17 78kDa glucose-regulated protein gi|25742763| 5.07 72,476 2 0.024 60 4 -2 
18 Myosin light chain MLC-1f gi|205485| 4.99 20,795 15 0.003 200 67 -2 
19 F1-ATPase, beta subunit gi|203033| 5.07 38,747 4 0.009 187 12 2 
20 Triose phosphate isomerase  gi|38512111| 7.07 27,223 10 0.006 152 59 2.1 
21 Phosphofructokinase gi|62825891| 8.07 86,159 5 0.040 89 7 2.2 
22 Pyruvate dehydrogenase gi|56090293| 6.2 39,305 3 0.044 37 10 2.6 
23 Pyruvate kinase gi|16757994| 6.63 58,303 13 0.013 283 30 2.7 
24 ATP synthase, mitochondrial F1 complex gi|149029719| 6.43 23,434 8 0.004 94 53 3.1 
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may be useful for the identification of new therapeutic tar-
gets, the development of better diagnostic criteria, the im-
proved monitoring of disease progression and the biomedical 
evaluation of experimental treatment regimes. 
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